美女免费一级视频在线观看
At her Senate hearing, ousted Centers for Disease Control and Prevention (CDC) director Susan Monarez said Health and Human Services Secretary Robert F. Kennedy Jr. planned to change the pediatric vaccine schedule and requested that she support it. After she refused, Monarez said Kennedy was “very upset” and further pressured her in the lead-up to her firing. (MSNBC)
Eli Lilly’s oral obesity pill, orforglipron, was more effective in lowering blood sugar and weight than Novo Nordisk’s oral version of Ozempic known as Rybelsus, according to data from Lilly’s Phase 3 trial. The highest dose of orforglipron resulted in 8.2% weight loss compared to the highest dose of Rybelsus, which led to 5.3% weight loss. (STAT News)
Novo views its clinical trial investigating semaglutide for Alzheimer’s disease as a “lottery ticket,” due to both the uncertainty and the potential around its future. The drugmaker is expected to release data from the clinical trial exploring the obesity medication’s potential in slowing down cognitive decline by the end of the year. (Reuters)
Big pharmaceutical companies have ditched or paused nearly £2 billion in planned U.K. investments so far this year, causing “suffering” to patients, as ministers gear up for discussions with Donald Trump amid a row over drug pricing. In total, decisions over 13 major projects or companies have damaged the UK’s pharma industry since 2022, also including site closures and stock market delistings. (The Guardian)
GSK said it will invest $30 billion into U.S. manufacturing and R&D over the next five years as pressures from potential tariffs rise. The investment includes a new factory in Pennsylvania that will manufacture respiratory and cancer products. (Endpoints News)
To read yesterday’s edition of Five things for pharma marketers to know, click here.